


## AMENDMENTS TO THE CLAIMS

### IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



wherein

a is 0 and b ~~are equal to~~ is 0 and or 1; wherein the values of 0 and 1 are a direct bond and -CH<sub>2</sub>-, respectively, and wherein the -CH<sub>2</sub>- group is optionally substituted 1 to 2 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups: -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, -O-alkyl, -O-aryl, or -hydroxyl;

W is -N(R<sub>4</sub>)-;

wherein

R<sub>4</sub> is

- a) -hydrogen;
- b) -alkyl;
- c) -L<sub>2</sub>-D-G;
- d) -L<sub>2</sub>-D-alkyl;
- e) -L<sub>2</sub>-D-aryl;
- f) -L<sub>2</sub>-D-heteroaryl;
- g) -L<sub>2</sub>-D-cycloalkyl;
- h) -L<sub>2</sub>-D-heterocyclyl;
- i) -L<sub>2</sub>-D-arylene-alkyl;

- j) – L<sub>2</sub>-D-alkylene-cycloalkyl;
- k) – L<sub>2</sub>-D-alkylene-heterocyclyl;
- l) – L<sub>2</sub>-D-alkylene-aryl;
- m) – L<sub>2</sub>-D-alkylene-heteroaryl;
- n) – L<sub>2</sub>-D-alkylene-arylene-alkyl;
- o) – L<sub>2</sub>-D-alkylene-heteroarylene-alkyl;
- p) – L<sub>2</sub>-D-alkyl-G;
- q) – L<sub>2</sub>-D-aryl-G;
- r) – L<sub>2</sub>-D-heteroaryl-G;
- s) – L<sub>2</sub>-D-cycloalkyl-G;
- t) – L<sub>2</sub>-D-heterocyclyl-G;
- u) – L<sub>2</sub>-D-arylene-alkyl-G;
- v) – L<sub>2</sub>-D-alkylene-cycloalkyl-G;
- w) – L<sub>2</sub>-D-alkylene-heterocyclyl-G;
- x) – L<sub>2</sub>-D-alkylene-aryl-G;
- y) – L<sub>2</sub>-D-alkylene-heteroaryl-G;
- z) – L<sub>2</sub>-D-alkylene-arylene-alkyl-G; or
- aa) – L<sub>2</sub>-D-alkylene-heteroarylene-alkyl-G;

wherein


L<sub>2</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

D is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>5</sub>)-, -C(O)-, -CON(R<sub>5</sub>)-, -N(R<sub>6</sub>)C(O)-, -N(R<sub>6</sub>)CON(R<sub>5</sub>)-, -N(R<sub>5</sub>)C(O)O-, -OC(O)N(R<sub>5</sub>)-, -N(R<sub>5</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>5</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, or -N(R<sub>5</sub>)SO<sub>2</sub>N(R<sub>6</sub>)-, -N=N-, or -N(R<sub>5</sub>)-N(R<sub>6</sub>)-,

wherein R<sub>5</sub> and R<sub>6</sub> are independently selected from the group

consisting of : -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

G is -H, -alkyl, -CN, -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere, -NR<sub>7</sub>R<sub>8</sub>,



wherein

$L_{10}$  is alkyline, cycloalkyline, heteroaryline, aryline, or heterocyclyline;

$L_{12}$  is -O-, -C(O)-N(R<sub>40</sub>)-, -C(O)-O-, -C(O)-, or -N(R<sub>40</sub>)-CO-N(R<sub>41</sub>)-;

$L_{13}$  is hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, or -alkylene-aryl;

$L_{11}$  is hydrogen, alkyl, alkenyl, alkynyl, -alkylene-aryl, -alkylene - heteroaryl, alkylene-O-alkylene-aryl, -alkylene-S-alkylene-aryl, -alkylene-O-alkyl, -alkylene-S-alkyl, -alkylene-NH<sub>2</sub>, -alkylene-OH, -alkylene-SH, -alkylene-C(O)-OR<sub>42</sub>, -alkylene-C(O)-NR<sub>42</sub>R<sub>43</sub>, -alkylene-NR<sub>42</sub>R<sub>43</sub>, -alkylene-N(R<sub>42</sub>)-C(O)-R<sub>43</sub>, , -alkylene-N(R<sub>42</sub>)-S(O<sub>2</sub>)-R<sub>43</sub>, or the side chain of a natural or non – natural amino acid;

R<sub>42</sub> and R<sub>43</sub> are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;

wherein


R<sub>42</sub> and R<sub>43</sub> may be taken together to form a ring having the formula – (CH<sub>2</sub>)<sub>q</sub>-Y-(CH<sub>2</sub>)<sub>r</sub>- bonded to the nitrogen atom to which R<sub>11</sub> and R<sub>12</sub> are attached, wherein q and r are, independently, 1, 2, 3, or 4; Y is -CH<sub>2</sub>-, -C(O)-, -O-, -N(H)-, -S-, -S(O)-, -SO<sub>2</sub>-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO<sub>2</sub>-, -SO<sub>2</sub>N(H)-, -(O)CO-, -NHCO<sub>2</sub>NH-, -OC(O)-, -N(R<sub>44</sub>)-, -N(C(O)R<sub>44</sub>)-, -N(C(O)NHR<sub>44</sub>)-, -N(SO<sub>2</sub>NHR<sub>44</sub>)-, -N(SO<sub>2</sub>R<sub>44</sub>)-, or -N(C(O)OR<sub>44</sub>)-; or

R<sub>42</sub> and R<sub>43</sub> may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;

R<sub>40</sub>, R<sub>41</sub>, and R<sub>44</sub> are independently selected from the group consisting of: hydrogen, aryl, alkyl, or alkylene-aryl;

and wherein

R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, -alkyl, -L<sub>3</sub>-E-alkyl, -L<sub>3</sub>-E-aryl, -C(O)-alkyl, -C(O)-



aryl, -SO<sub>2</sub>-alkyl, -SO<sub>2</sub>-aryl, and ;

wherein

R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are independently selected from the group consisting of : -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

L<sub>3</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

E is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>12</sub>)-, -C(O)-, -CON(R<sub>12</sub>)-, -N(R<sub>12</sub>)C(O)-, -N(R<sub>12</sub>)CON(R<sub>13</sub>)-, -N(R<sub>12</sub>)C(O)O-, -OC(O)N(R<sub>12</sub>)-, -N(R<sub>12</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>12</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>12</sub>)SO<sub>2</sub>N(R<sub>13</sub>)-, -N=N-, or -N(R<sub>12</sub>)-N(R<sub>13</sub>)-,

wherein

R<sub>12</sub> and R<sub>13</sub> are independently selected from the group consisting of : -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

A is hydrogen, -alkyl, -alkenyl, or -alkynyl;

X is

- a) -C(O)-;

R<sub>1</sub> is

- a) -hydrogen;
- b) -fluoro
- c) -chloro
- d) -bromo
- e) -iodo
- f) -cyano
- g) -alkyl;
- h) -aryl;
- i) -alkylene-aryl;
- j) -heteroaryl;
- k) -alkylkene-heteroaryl;
- l) -cycloalkyl;
- m) -alkylene-cycloalkyl
- n) - heterocyclyl; or
- o) - alkylene-heterocyclyl;

R<sub>2</sub> is

- a) -perfluoroalkyl;
- b) -J-R<sub>14</sub>;
- c) -alkyl;
- d) -aryl;
- e) -heteroaryl;
- f) -heterocyclyl;
- g) -cycloalkyl;
- h) -L<sub>4</sub> -aryl;
- i) -L<sub>4</sub>-arylene-aryl;
- j) -L<sub>4</sub>-arylene-alkyl;

- k) -arylene-alkyl;
- l) -arylene-arylene-alkyl;
- m) -J-alkyl;
- n) -J-aryl;
- o) -J-alkylene-aryl;
- p) -J-arylene-alkyl;
- q) -J-alkylene-arylene-aryl;
- r) -J-arylene-arylene-aryl;
- s) -J-alkylene-arylene-alkyl;
- t)  $-L_4$ -J-alkylene-aryl;
- u) -arylene-J-alkyl;
- v)  $-L_4$ -J-aryl;
- w)  $-L_4$ -J-heteroaryl;
- x)  $-L_4$ -J-cycloalkyl;
- y)  $-L_4$ -J-cycloalkylene-alkyl;
- z)  $-L_4$ -J-heterocyclyl;
- aa)  $-L_4$ -J-arylene-alkyl;
- bb)  $-L_4$ -J-alkylene-arylene-alkyl;
- cc)  $-L_4$ -J-alkyl;
- dd)  $-L_4$ -J- $R_{14}$ ;
- ee)  $-L_4$ -J-alkylene- $R_{14}$ ;
- ff)  $-J$ - $L_4$ - $R_{14}$ ;
- gg) -arylene-J- $R_{14}$ ;
- hh)  $-L_4$ -arylene-J-alkyl;
- ii)  $-L_4$ -alkylene-J-alkyl;
- jj)  $-L_4$ -arylene-J-aryl; or
- kk) -hydrogen;

wherein


$L_4$  is a direct bond, -alkylene, -alkenylene, -alkynylene, heterocyclylene, cycloalkylene, arylene, or heteroarylene;

J is a direct bond,  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{N}(\text{R}_{15})-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CON}(\text{R}_{15})-$ ,  $-\text{N}(\text{R}_{15})\text{C}(\text{O})-$ ,  
 $-\text{N}(\text{R}_{15})\text{CON}(\text{R}_{16})-$ ,  $-\text{N}(\text{R}_{15})\text{C}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}_{15})-$ ,  $-\text{N}(\text{R}_{15})\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}_{15})-$ ,  
 $-\text{C}(\text{O})-\text{O}-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O}_2)-$ ,  $-\text{N}(\text{R}_{15})\text{SO}_2\text{N}(\text{R}_{16})-$ ,  
 $-\text{N}=\text{N}-$ , or  $-\text{N}(\text{R}_{15})-\text{N}(\text{R}_{16})-$ ,

wherein

$\text{R}_{15}$  and  $\text{R}_{16}$  are independently selected from the group consisting of :  
 $-\text{hydrogen}$ ,  $-\text{alkyl}$ ,  $-\text{aryl}$ ,  $-\text{arylene-alkyl}$ ,  $-\text{alkylene-aryl}$ , and  
 $-\text{alkylene-arylene-alkyl}$ ,

$\text{R}_{14}$  is:  $-\text{hydrogen}$ ,  $-\text{alkyl}$ ,  $-\text{aryl}$ ,  $-\text{arylene-alkyl}$ ,  $-\text{alkylene-aryl}$ ,  $-\text{alkylene-arylene-alkyl}$ , or



wherein

$\text{L}_{14}$  is  $-\text{alkylene}$ ,  $-\text{cycloalkylene}$ ,  $-\text{heteroarylene}$ ,  $-\text{arylene}$ , or  $-\text{heterocyclylene}$ ;

$\text{L}_{16}$  is  $-\text{O}-$ ,  $-\text{C}(\text{O})-\text{N}(\text{R}_{45})-$ ,  $-\text{C}(\text{O})-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{N}(\text{R}_{45})-\text{CO}-\text{N}(\text{R}_{46})-$ ;

$\text{L}_{17}$  is  $-\text{hydrogen}$ ,  $-\text{alkyl}$ ,  $-\text{alkenyl}$ ,  $-\text{alkynyl}$ ,  $-\text{heterocyclyl}$ ,  $-\text{heteroaryl}$ , or  $-\text{alkylene-aryl}$ ;

$\text{L}_{15}$  is  $-\text{hydrogen}$ ,  $-\text{alkyl}$ ,  $-\text{alkenyl}$ ,  $-\text{alkynyl}$ ,  $-\text{alkylene-aryl}$ ,  $-\text{alkylene-heteroaryl}$ ,  $-\text{alkylene-O-alkylene-aryl}$ ,  $-\text{alkylene-S-alkylene-aryl}$ ,  $-\text{alkylene-O-alkyl}$ ,  $-\text{alkylene-S-alkyl}$ ,  $-\text{alkylene-NH}_2$ ,  $-\text{alkylene-OH}$ ,  $-\text{alkylene-SH}$ ,  $-\text{alkylene-C}(\text{O})-\text{OR}_{47}$ ,  $-\text{alkylene-C}(\text{O})-\text{NR}_{47}\text{R}_{48}$ ,  $-\text{alkylene-NR}_{47}\text{R}_{48}$ ,  $-\text{alkylene-N}(\text{R}_{47})-\text{C}(\text{O})-\text{R}_{48}$ ,  $-\text{alkylene-N}(\text{R}_{47})-\text{S}(\text{O}_2)-\text{R}_{48}$ , or the side chain of a natural or non-natural amino acid;

$\text{R}_{47}$  and  $\text{R}_{48}$  are independently selected from the group consisting of  $-\text{hydrogen}$ ,  $-\text{aryl}$ ,  $-\text{alkyl}$ , and  $-\text{alkylene-aryl}$ ;

R<sub>47</sub> and R<sub>48</sub> may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring, R<sub>45</sub> and R<sub>46</sub> are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;

R<sub>3</sub> is

- a) -hydrogen
- b) -alkyl
- c) -aryl;
- d) -alkylene-cycloalkyl;
- e) -arylene-alkyl;
- f) -alkylene-aryl; or
- g) -alkylene-heteroaryl;

Ar<sub>1</sub> is an aryl or fused cycloalkylaryl group optionally substituted 1 to 7 times and if Ar<sub>1</sub> is phenyl, the phenyl has 1 to 5 substituents, wherein the substituents for Ar<sub>1</sub> are selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -alkyl;
- i) -aryl;
- j) -heteroaryl;
- k) -heterocyclyl;
- l) -cycloalkyl;
- m) -L<sub>5</sub>-aryl;



- n) - L<sub>5</sub>-arylene-aryl;
- o) - L<sub>5</sub>-arylene-alkyl;
- p) -arylene-alkyl;
- q) -arylene-arylene-alkyl;
- r) -K-alkyl;
- s) -K-aryl;
- t) -K-alkylene-aryl;
- u) -K-arylene-alkyl;
- v) -K-alkylene-arylene-aryl;
- w) -K-arylene-arylene-aryl;
- x) -K-alkylene-arylene-alkyl;
- y) - L<sub>5</sub>-K-alkylene-aryl;
- z) -arylene-K-alkyl;
- aa) - L<sub>5</sub>-K-aryl;
- bb) - L<sub>5</sub>-K-heteroaryl;
- cc) - L<sub>5</sub>-K-cycloalkyl;
- dd) - L<sub>5</sub>-K-heterocyclyl;
- ee) - L<sub>5</sub>-K-arylene-alkyl;
- ff) - L<sub>5</sub>-K-alkylene-arylene-alkyl;
- gg) - L<sub>5</sub>-K-alkyl; and
- hh) -arylene-K-R<sub>17</sub>;

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

K is a direct bond, -CH<sub>2</sub>-, -N(R<sub>18</sub>)-, -C(O)-, -CON(R<sub>18</sub>)-, -N(R<sub>18</sub>)C(O)-, -N(R<sub>18</sub>)CON(R<sub>19</sub>)-, -N(R<sub>18</sub>)C(O)O-, -OC(O)N(R<sub>18</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>18</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>N(R<sub>19</sub>)-, -N=N-, or -N(R<sub>18</sub>)-N(R<sub>19</sub>)-,

wherein

R<sub>17</sub>, R<sub>18</sub>, and R<sub>19</sub> are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

Ar<sub>2</sub> is an arylene, fused arylcycloalkylene, or fused cycloalkylarylene group optionally substituted 1 to 7 times;

L<sub>1</sub> is a direct bond, -CH<sub>2</sub>-, -O-, alkylene, alkenylene, -O-alkylene-, -alkylene-O-, -N(R<sub>23</sub>)-, -C(O)-, -CON(R<sub>23</sub>)-, -N(R<sub>23</sub>)C(O)-, -N(R<sub>23</sub>)CON(R<sub>24</sub>)-, -N(R<sub>23</sub>)C(O)O-, -OC(O)N(R<sub>23</sub>)-, -N(R<sub>23</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>23</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>23</sub>)SO<sub>2</sub>N(R<sub>24</sub>)-, -N=N-, or -N(R<sub>23</sub>)-N(R<sub>24</sub>)-;

wherein



R<sub>23</sub> and R<sub>24</sub> are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, alkylene-aryl, -alkylene-arylene-alkyl, and a direct bond;

T is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, or fused heterocyclylheteroaryl group optionally substituted 1 to 7 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -U-R<sub>25</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;

- n) -L<sub>7</sub>-aryl;
- o) -L<sub>7</sub>-arylene-aryl;
- p) -L<sub>7</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L<sub>7</sub>-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L<sub>7</sub>-U-aryl;
- cc) -L<sub>7</sub>-U-heteroaryl;
- dd) -L<sub>7</sub>-U-cycloalkyl;
- ee) -L<sub>7</sub>-U-heterocyclyl;
- ff) -L<sub>7</sub>-U-arylene-alkyl;
- gg) -L<sub>7</sub>-U-alkylene-arylene-alkyl;
- hh) -L<sub>7</sub>-U-alkyl;
- ii) -L<sub>7</sub>-U-alkylene-aryl- R<sub>25</sub>;
- jj) -L<sub>7</sub>-U-alkylene-heteroaryl- R<sub>25</sub>;
- kk) -arylene-U-alkylene- R<sub>25</sub>;
- ll) -heteroarylene-U-alkylene- R<sub>25</sub>;
- mm) -L<sub>7</sub>-U-aryl- R<sub>25</sub>;
- nn) -L<sub>7</sub>-U-heteroarylene- R<sub>25</sub>;
- oo) -L<sub>7</sub>-U-heteroaryl- R<sub>25</sub>;
- pp) -L<sub>7</sub>-U-cycloalkyl- R<sub>25</sub>;
- qq) -L<sub>7</sub>-U-heterocyclyl- R<sub>25</sub>;
- rr) -L<sub>7</sub>-U-arylene-alkyl- R<sub>25</sub>;

ss) -L<sub>7</sub>-U-heteroarylene-alkyl- R<sub>25</sub>;  
 tt) -L<sub>7</sub>-U-alkylene-arylene-alkyl- R<sub>25</sub>;  
 uu) -L<sub>7</sub>-U-alkylene-heteroarylene-alkyl- R<sub>25</sub>;  
 vv) -L<sub>7</sub>-U-alkylene-cycloalkylene-alkyl- R<sub>25</sub>;  
 ww) -L<sub>7</sub>-U-alkylene-heterocyclylene-alkyl- R<sub>25</sub>;  
 xx) -L<sub>7</sub>-U-alkyl- R<sub>25</sub>;  
 yy) -L<sub>7</sub>-U- R<sub>25</sub>;  
 zz) -arylene-U- R<sub>25</sub>;  
 aaa) -heteroarylene-U- R<sub>25</sub>;  
 bbb) -heterocyclylene-U- R<sub>25</sub>;  
 ccc) -U-alkylene- R<sub>25</sub>;  
 ddd) -U-arylene- R<sub>25</sub>;  
 eee) -U-heteroarylene- R<sub>25</sub>;  
 fff) -U-alkylene-arylene- R<sub>25</sub>;  
 ggg) -U-alkylene-heteroarylene- R<sub>25</sub>;  
 hhh) -U-heteroarylene-alkylene- R<sub>25</sub>;  
 iii) -U-arylene-alkylene- R<sub>25</sub>;  
 jjj) -U-cycloalkylene-alkylene- R<sub>25</sub>;  
 kkk) -U-heterocyclylene-alkylene- R<sub>25</sub>;  
 ll) -U-alkylene-arylene-alkyl- R<sub>25</sub>;  
 mmm) -U-alkylene-heteroarylene-alkyl- R<sub>25</sub>;



ppp) -hydrogen;


wherein

$L_7$  is a direct bond, --alkylene, -alkenylene, or -alkynylene;

$U$  is a direct bond,  $-CH_2-$ ,  $-O-$ ,  $-N(R_{26})-$ ,  $-C(O)-$ ,  $-CON(R_{26})-$ ,  $-N(R_{26})C(O)-$ ,  $-N(R_{26})CON(R_{27})-$ ,  $-N(R_{26})C(O)O-$ ,  $-OC(O)N(R_{26})-$ ,  $-N(R_{26})SO_2-$ ,  $-SO_2N(R_{26})-$ ,  $-C(O)-O-$ ,  $-O-C(O)-$ ,  $-S-$ ,  $-S(O)-$ ,  $-S(O_2)-$ ,  $-N(R_{26})SO_2N(R_{27})-$ ,  $N=N-$ , or  $-N(R_{26})-N(R_{27})-$ ;

wherein

$R_{26}$  and  $R_{27}$  are independently selected from the group consisting of : -  
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and  
-alkylene-arylene-alkyl;



$Y_2$  is hydrogen,  $-CO_2H$ , -alkylene-aryl, -alkyl, -aryl, -heteroaryl,  
-heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

$R_{25}$  is  $-SO_3H$ ,  $-P(O)(OH)_2$ ,  $-P(O)(O-alkyl)(OH)$ ,  $-CO_2H$ ,  $-CO_2$ -alkyl, an  
acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or  
-alkylene-arylene-alkyl.

or a pharmaceutically acceptable salt or solvatethereof.

2. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $W$  is  $-N(R_4)-$ , wherein  $R_4$  is -alkyl,  $-L_2$ -D-alkyl, or  $-L_2$ -D-aryl, wherein  $L_2$  is alkylene, and  $D$  is a direct bond,  $-C(O)-$  or  $-O-$ .

3. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $W$  is  $-N(R_4)-$ , wherein  $R_4$  is hydrogen.

4. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein W is -N(R<sub>4</sub>)-, wherein R<sub>4</sub> is -L<sub>2</sub>-D-G, wherein L<sub>2</sub> is alkenyl or alkynyl, D is a direct bond, and G is hydrogen or alkyl.

5. (Canceled).

6. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>1</sub> is hydrogen or aryl.

7. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>2</sub> is: -alkyl, -aryl, -L<sub>4</sub>-J-cycloalkyl, arylene-alkyl, -L<sub>4</sub>-arylene-J-alkyl, or -J-alkyl, wherein L<sub>4</sub> is alkylene or alkenylene, and J is a direct bond or -O-.

8. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>3</sub> is -H; X is -C(O)-; R<sub>2</sub> is -L<sub>4</sub>-arylene-J-alkyl, -L<sub>4</sub>-J-cycloalkylene-alkyl or -L<sub>4</sub>-J-alkylene-aryl, wherein L<sub>4</sub> is alkylene, alkenylene, or a direct bond; and J is a direct bond, -O-, or -NH-.

9. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R<sub>3</sub> is hydrogen.

10. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>1</sub> is a phenyl or naphthyl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -alkyl;
- i) -aryl;
- j) -heteroaryl;
- k) -heterocyclyl;
- l) -cycloalkyl;
- m) - L<sub>5</sub>-aryl;
- n) - L<sub>5</sub>-arylene-aryl;
- o) - L<sub>5</sub>-arylene-alkyl;
- p) -arylene-alkyl;
- q) -arylene-arylene-alkyl;
- r) -K-alkyl;
- s) -K-aryl;
- t) -K-alkylene-aryl;
- u) -K-arylene-alkyl;
- v) -K-alkylene-arylene-aryl;
- w) -K-arylene-arylene-aryl;
- x) -K-alkylene-arylene-alkyl;
- y) - L<sub>5</sub>-K-alkylene-aryl;
- z) -arylene-K-alkyl;
- aa) - L<sub>5</sub>-K-aryl;
- bb) - L<sub>5</sub>-K-heteroaryl;
- cc) - L<sub>5</sub>-K-cycloalkyl;
- dd) - L<sub>5</sub>-K-heterocyclyl;
- ee) - L<sub>5</sub>-K-arylene-alkyl;

ff) - L<sub>5</sub>-K-alkylene-arylene-alkyl;

gg) - L<sub>5</sub>-K-alkyl;

and

hh) -arylene-K-R<sub>17</sub>;

wherein

L<sub>5</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

K is a direct bond, -CH<sub>2</sub>-, -N(R<sub>18</sub>)-, -C(O)-, -CON(R<sub>18</sub>)-, -N(R<sub>18</sub>)C(O)-, -N(R<sub>18</sub>)CON(R<sub>19</sub>)-, -N(R<sub>18</sub>)C(O)O-, -OC(O)N(R<sub>18</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>18</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>18</sub>)SO<sub>2</sub>N(R<sub>19</sub>)-, -N=N-, or -N(R<sub>18</sub>)-N(R<sub>19</sub>)-,

wherein

R<sub>17</sub>, R<sub>18</sub>, and R<sub>19</sub> are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

11. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>1</sub> is a phenyl group substituted 1 to 5 times with substituents independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo; and
- e) -nitro.

12. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenylene or naphthylene group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:



- a) -fluoro;



- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R<sub>20</sub>;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L<sub>6</sub>-aryl;
- o) -L<sub>6</sub>-arylene-aryl;
- p) -L<sub>6</sub>-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L<sub>6</sub>-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L<sub>6</sub>-Q-aryl;
- cc) -L<sub>6</sub>-Q-heteroaryl;
- dd) -L<sub>6</sub>-Q-cycloalkyl;
- ee) -L<sub>6</sub>-Q-heterocyclyl;
- ff) -L<sub>6</sub>-Q-arylene-alkyl;

gg) -L<sub>6</sub>-Q-alkylene-arylene-alkyl;  
 hh) -L<sub>6</sub>-Q-alkyl;  
 ii) -L<sub>6</sub>-Q-alkylene-aryl-R<sub>20</sub>;  
 jj) -L<sub>6</sub>-Q-alkylene-heteroaryl-R<sub>20</sub>;  
 kk) -arylene-Q-alkylene- R<sub>20</sub>;  
 ll) -heteroarylene-Q-alkylene- R<sub>20</sub>;  
 mm) -L<sub>6</sub>-Q-aryl- R<sub>20</sub>;  
 nn) -L<sub>6</sub>-Q-heteroarylene- R<sub>20</sub>;  
 oo) -L<sub>6</sub>-Q-heteroaryl- R<sub>20</sub>;  
 pp) -L<sub>6</sub>-Q-cycloalkyl- R<sub>20</sub>;  
 qq) -L<sub>6</sub>-Q-heterocyclyl- R<sub>20</sub>;  
 rr) -L<sub>6</sub>-Q-arylene-alkyl- R<sub>20</sub>;  
 ss) -L<sub>6</sub>-Q-heteroarylene-alkyl- R<sub>20</sub>;  
 tt) -L<sub>6</sub>-Q-alkylene-arylene-alkyl- R<sub>20</sub>;  
 uu) -L<sub>6</sub>-Q-alkylene-heteroarylene-alkyl- R<sub>20</sub>;  
 vv) -L<sub>6</sub>-Q-alkylene-cycloalkylene-alkyl- R<sub>20</sub>;  
 ww) -L<sub>6</sub>-Q-alkylene-heterocyclylene-alkyl- R<sub>20</sub>;  
 xx) -L<sub>6</sub>-Q-alkyl- R<sub>20</sub>;  
 yy) -L<sub>6</sub>-Q- R<sub>20</sub>;  
 zz) -arylene-Q- R<sub>20</sub>;  
 aaa) -heteroarylene-Q- R<sub>20</sub>;  
 bbb) -heterocyclylene-Q- R<sub>18</sub>;  
 ccc) -Q-alkylene- R<sub>20</sub>;  
 ddd) -Q-arylene- R<sub>20</sub>;  
 eee) -Q-heteroarylene- R<sub>20</sub>;  
 fff) -Q-alkylene-arylene- R<sub>20</sub>;  
 ggg) -Q-alkylene-heteroarylene- R<sub>20</sub>;  
 hhh) -Q-heteroarylene-alkylene- R<sub>20</sub>;  
 iii) -Q-arylene-alkylene- R<sub>20</sub>;  
 jjj) -Q-cycloalkylene-alkylene- R<sub>20</sub>;  
 kkk) -Q-heterocyclylene-alkylene- R<sub>20</sub>;

lll) -Q-alkylene-arylene-alkyl- R<sub>20</sub>; or  
 mmm) -Q-alkylene-heteroarylene-alkyl- R<sub>20</sub>;



ppp) -hydrogen,


wherein

L<sub>0</sub> is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, -CH<sub>2</sub>-, -O-, -N(R<sub>21</sub>)-, -C(O)-, -CON(R<sub>21</sub>)-, -N(R<sub>21</sub>)C(O)-, -N(R<sub>21</sub>)CON(R<sub>22</sub>)-, -N(R<sub>21</sub>)C(O)O-, -OC(O)N(R<sub>21</sub>)-, -N(R<sub>21</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sub>21</sub>)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O<sub>2</sub>)-, -N(R<sub>21</sub>)SO<sub>2</sub>N(R<sub>22</sub>)-, N=N-, or -N(R<sub>21</sub>)-N(R<sub>22</sub>)-;

wherein

R<sub>21</sub> and R<sub>22</sub> are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;



Z is hydrogen, -CO<sub>2</sub>H, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R<sub>20</sub> is -SO<sub>3</sub>H, -P(O)(OH)<sub>2</sub>, -P(O)(O-alkyl)(OH), -CO<sub>2</sub>H, -CO<sub>2</sub>-alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

13. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenylene or naphthylene group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q-R<sub>20</sub>;
- f) -alkyl;
- g) -aryl;
- h) -arylene-alkyl;
- i) -Q-alkyl; and
- j) -arylene-Q-alkyl;

wherein

Q is: -CH<sub>2</sub>-, -O-, -C(O)-, or -C(O)-O-; and

R<sub>20</sub> is: -hydrogen, -alkyl, -aryl, cycloalkyl, -alkenyl, -CO<sub>2</sub>H, or an acid isostere.

14. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>2</sub> is a phenylene group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q-R<sub>20</sub>;
- f) -alkyl;
- g) -phenyl;

- h) -phenylene-alkyl;
- i) -Q-alkyl; and
- j) -phenylene-Q-alkyl;


wherein

Q is:  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})-\text{O}-$ ; and

$\text{R}_{20}$  is: -hydrogen, -alkyl, -phenyl, -cycloalkyl, alkenyl, or  $-\text{CO}_2\text{H}$ .

15. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $\text{Ar}_2$  is a phenylene group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of :


- a) -Q-alkyl;
- b) -Q-arylene- $\text{R}_{20}$ ;
- c) -Q-alkylene-arylene- $\text{R}_{20}$ ; and



wherein

Q is:  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})-\text{O}-$ ;

Z is  $-\text{CO}_2\text{H}$  or an acid isostere;



$\text{R}_{20}$  is:  $-\text{CO}_2\text{H}$  or an acid isostere.

16. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein  $\text{L}_1$  is -O-alkylene- or a direct bond.

17. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein T is an aryl group substituted by -U-alkylene-R<sub>25</sub>, wherein U is -O- or a direct bond and R<sub>25</sub> is -CO<sub>2</sub>H or an acid isostere.

18. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X and R<sub>2</sub> together form a group selected from the group consisting of:

tert-butoxycarbonyl, tert-butyl-methyl-carbonyl, 4-cyclohexyl-butyryl, 3-cyclohexyl-propionyl, 2-cyclohexyl-acetyl, 4-tert-butyl-phenyl)-carbonyl, 4-(4'-methoxyphenyl)-butyryl, 4-(4'-methoxyphenyl)-butyryl, 3-(4'-methoxyphenyl)-propionyl, 3-(3'-methoxyphenyl)-propionyl, 3-(4'-methoxy-phenyl)-acryl, 3-(4'-chloro-phenyl)-acryl, 2-(4'-methoxy-phenyl)-acetyl, 2-(4'-chloro-phenyl)-acetyl, 2-(4'-methylsulfonyl-phenyl)-acetyl, 2-(4'-methylsulfonyl-phenyl)-acetyl, 4-(4'-chloro-2'-methyl-phenoxy)-butyryl, 4-(4'-methoxyphenyl)-butyryl, and 4-(4'-cyclohexyl)-propyl.

19. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein a equals 0, and the groups T, L<sub>1</sub>, and Ar<sub>2</sub> together form a group selected from the group consisting of: 4'-n-butoxy-3'-n-butoxy carbonyl phenyl, and 4'-n-butoxy-3'-carboxyl phenyl.

20. (Previously Presented) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ar<sub>1</sub> is selected from the group consisting of naphthyl, 4-nitrophenyl, 4-chlorophenyl, 3-chlorophenyl, 3, 4-dichlorophenyl, 2, 4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 4-cyanophenyl, 4-bromophenyl, and pentafluorophenyl.

21. (Previously Presented) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is selected from the group consisting of:

- 2-[3-(4'-Methoxyphenyl)-propionylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(4'-nitrophenyl)]imidazole;
- 2-[3-(4'-Methoxy-phenyl)-acrylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(4'-nitrophenyl)]imidazole;
- 2-[4-(4'-Methoxyphenyl)-butyryl amino]-2-(4'-n-butoxy-3'-carboxy phenyl)-2-ethyl [4-(2', 4'-dichlorophenyl)] imidazole;
- 2-[4-(4'-Cyclohexyl)-propanoylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(2',4'-dichlorophenyl)] imidazole;
- N-[(1*S*)-2-(4-(1,1-Dicarboxymethoxy)phenyl)-1-[4-(2,4-dichlorophenyl)-1*H*-1-(1-butyl)imidazol-2-yl]ethyl]-4-tert-butylcyclohexanecarboxamide;
- 4-(4-[(2*S*)-2-[(4-tert-Butyl-cyclohexanecarbonyl)-amino]-2-[1-butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]-ethyl]-phenoxymethyl)-benzoic acid;
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]}-(2*S*)-2-[2-(4-methoxy-phenyl)-acetylamino]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-{4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]}-(2*S*)-2-(2-cyclopentyl-acetylamino)-ethyl}-phenoxymethyl}-benzoic acid;
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]}-(2*S*)-2-[(*trans*-4-methyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]}-(2*S*)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-(4-[(2*S*)-2-[(4-tert-Butyl-cyclohexanecarbonyl)-amino]-2-[4-(2,4-dichloro-phenyl)-(*E*)-1-pent-2-enyl-1*H*-imidazol-2-yl]-ethyl]-phenoxymethyl)-benzoic acid;
- 4-(4-{2-[4-(2,4-Dichloro-phenyl)-(*E*)-1-pent-2-enyl-1*H*-imidazol-2-yl]}-(2*S*)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-(4-{2-[1-But-2-ynyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]}-(2*S*)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-(4-[(2*S*)-2-[(4-tert-Butyl-cyclohexanecarbonyl)-amino]-2-[1-butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]-ethyl]-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(trans-4-ethyl-cyclohexane-carbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[4-(2,4-Dichloro-phenyl)-1-pent-2-enyl-1H-imidazol-2-yl]- (2S)-2-[(trans-4-ethyl-cyclohexane-carbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-But-2-ynyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(trans-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[4-(3-fluorobenzylcarbonyl)-butyrylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[2-(4-methoxy-phenyl)-acetylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[2-(2,4-difluorophenyl)-acetylamino]-ethyl}-phenoxy)-benzoic acid;

4-{4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-(4-methoxy-benzoylamino)-ethyl]-phenoxy}-benzoic acid;

4-{4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-(3,5-difluoro-benzoylamino)-ethyl]-phenoxy}-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(2,4-difluoro-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-methoxy-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(3-methoxy-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-trifluoromethyl-phenyl)-2-(2S)-isobutyrylamino-propionylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-tert-butyl-phenyl)-(2S)-2-isobutyrylamino-propionylamino]-ethyl}-phenoxy)-benzoic acid; and

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[4-(4-chloro-phenyl)-(3S)-3-isobutyrylamino-butyrylamino]-ethyl}-phenoxy)-benzoic acid;

or pharmaceutically acceptable salts thereof.

22. (Previously Presented) A pharmaceutically composition comprising a compound as claimed in claim 1.



23. (Previously Presented) The pharmaceutical composition of claim 22, wherein said compound is a topical formulation.

24. (Previously Presented) The pharmaceutical composition of claim 23, wherein the pharmaceutical composition is suitable for administration of said compound in a formulation ratio of 0.1% to 99% of compound to topical excipient.

25. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1 sufficient to inhibit protein tyrosine phosphatase.

26. (Original) The pharmaceutical composition of claim 25, in the form of an oral dosage or parenteral dosage unit.

27. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.003 to 500 mg/kg of body weight per day.

28. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

29. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

30. (Original) The pharmaceutical composition of claim 25, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

31. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

33-35. (canceled).

36. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat glucose intolerance.

37. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

38. (canceled).

39. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

40-62. (canceled).

63. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 2.

64. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 3.

65. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 4.

66. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 6.

67. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 7.

68. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 8.

69. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 9.

70. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 10.

71. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 11.

72. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 12.

73. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 13.

74. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 14.

75. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 15.

76. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 16.

77. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 17.

78. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 18.

79. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 19.

80. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 20.

81. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 21.